There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To characterize, directly and for the first time, the membrane transport and metabolism
of pralatrexate, a new-generation dihydrofolate reductase inhibitor approved for the
treatment for peripheral T-cell lymphoma.